Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-α for the treatment of renal cell carcinoma (RCC), at …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, …
Volatile trade continued on U.S.
Arrowhead Research Corp (NASDAQ:ARWR) announced financial results for its fiscal 2016 first quarter endedDecember 31, 2015. Fiscal 2016 First Quarter and Recent Company …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, dosed the first patient in the Phase 2b MONARCH combination study of ARC-520, …
Holiday shopping and festivities are in full swing, but several companies are slated to report earnings this week ahead of the holidays. Here’s what …
Two clinical stage biopharmaceutical companies, Arrowhead Research Corp (NASDAQ:ARWR) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), both provided a data update on pipeline drugs.
